Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Apoptosis and Angiogenesis

Additional Information

Published Date Jan 30, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4468
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Apoptosis and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Apoptosis and Angiogenesis.

    To find out more about Triple Analysis: Leukemia, Apoptosis and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Apoptosis and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Alnylam
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Arana Therapeutics
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
BioInvent
BioLineRx
Biomas
Bionovo
BioSante
Bioton
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
CJ Corp
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
CSL
Cue Biotech
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Genmab
Genta
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Glycotope
GPC Biotech
Green Cross
Hanmi
Harbor BioSciences
Hayashibara
Heber Biotec
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intradigm
Introgen Therapeutics
Isis Pharmaceuticals
ISU ABXIS
Italfarmaco
Johnson & Johnson
KAI Pharmaceuticals
KaloBios
Kalypsys
Kanisa
Karus Therapeutics
Keryx Biopharmaceuticals
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Morvus Technology
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
PanaGin
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Rosetta Genomics
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Sigma-Tau
Simcere Pharmaceuticals
Southern Research Institute
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Targa Therapeutics
TargeGen
Tau Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
ThromboGenics
Tigris Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Trion Pharma
UCB
UMN Pharma
Valeant
ValiRx
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
XBiotech
Xencor
Xerion
Yamasa Corporation
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
ABT-510
AEG-35156
aflibercept
alemtuzumab
alvocidib
AME-133
AMG-386
amonafide malate
amsacrine
Angiozyme
apatinib
APG-101
ARQ-197
AS-101
AS-1411
atrasentan
axitinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bisantrene
BMS-690514
bortezomib
bosutinib
brivanib alaninate
BZL-101
canfosfamide hydrochloride
cediranib
cenersen
cilengitide
cintredekin besudotox
cladribine
clofarabine
conatumumab
crolibulin
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
DI-17E6
dinaciclib
dovitinib lactate
dulanermin
E-7820
elacytarabine
endostatin
ENMD-2076
enocitabine
enzastaurin hydrochloride
everolimus
Exherin
foretinib
fosbretabulin tromethamine
gataparsen
gemtuzumab ozogamicin
GliaAtak
GT-111
HBP-347
HE-3235
histamine dihydrochloride
ibritumomab tiuxetan
icrucumab
idarubicin
idronoxil
imatinib mesilate
imetelstat
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
intetumumab
IPP-204106
JI-101
kahalalide F
lenvatinib
lestaurtinib
leukemia vaccine
linifanib
litronesib
lonaprisan
lumiliximab
LY-2275796
mapatumumab
MGCD-265
midostaurin
mitoxantrone
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
navitoclax
NGR-TNF
nilotinib
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
Oncohist
OTS-102
paclitaxel
PancAtak
panobinostat
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
PF-4856884
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
razoxane
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rituximab
sagopilone
seliciclib
sirolimus
sobuzoxane
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
tamibarotene
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
teniposide
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
tivozanib
TL-32711
TRC-105
triciribine phosphate
TRU-016
vandetanib
vismodegib
volasertib
volociximab
vosaroxin
XL-147
XL-184
XL-647
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Apoptosis and Angiogenesis.
    To find out more about Triple Analysis: Leukemia, Apoptosis and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Apoptosis and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Prostate Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Biliary Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Peptides). Learn More